Literature DB >> 33298562

Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans.

Haley L Dugan1, Jenna J Guthmiller2, Philip Arevalo3, Min Huang2, Yao-Qing Chen2, Karlynn E Neu1, Carole Henry2, Nai-Ying Zheng2, Linda Yu-Ling Lan1, Micah E Tepora2, Olivia Stovicek2, Dalia Bitar2, Anna-Karin E Palm2, Christopher T Stamper1, Siriruk Changrob2, Henry A Utset2, Lynda Coughlan4, Florian Krammer4, Sarah Cobey3, Patrick C Wilson5,2.   

Abstract

Humans are repeatedly exposed to variants of influenza virus throughout their lifetime. As a result, preexisting influenza-specific memory B cells can dominate the response after infection or vaccination. Memory B cells recalled by adulthood exposure are largely reactive to conserved viral epitopes present in childhood strains, posing unclear consequences on the ability of B cells to adapt to and neutralize newly emerged strains. We sought to investigate the impact of preexisting immunity on generation of protective antibody responses to conserved viral epitopes upon influenza virus infection and vaccination in humans. We accomplished this by characterizing monoclonal antibodies (mAbs) from plasmablasts, which are predominantly derived from preexisting memory B cells. We found that, whereas some influenza infection-induced mAbs bound conserved and neutralizing epitopes on the hemagglutinin (HA) stalk domain or neuraminidase, most of the mAbs elicited by infection targeted non-neutralizing epitopes on nucleoprotein and other unknown antigens. Furthermore, most infection-induced mAbs had equal or stronger affinity to childhood strains, indicating recall of memory B cells from childhood exposures. Vaccination-induced mAbs were similarly induced from past exposures and exhibited substantial breadth of viral binding, although, in contrast to infection-induced mAbs, they targeted neutralizing HA head epitopes. Last, cocktails of infection-induced mAbs displayed reduced protective ability in mice compared to vaccination-induced mAbs. These findings reveal that both preexisting immunity and exposure type shape protective antibody responses to conserved influenza virus epitopes in humans. Natural infection largely recalls cross-reactive memory B cells against non-neutralizing epitopes, whereas vaccination harnesses preexisting immunity to target protective HA epitopes.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33298562      PMCID: PMC8115023          DOI: 10.1126/scitranslmed.abd3601

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  61 in total

1.  Ecological and immunological determinants of influenza evolution.

Authors:  Neil M Ferguson; Alison P Galvani; Robin M Bush
Journal:  Nature       Date:  2003-03-27       Impact factor: 49.962

2.  Highly conserved protective epitopes on influenza B viruses.

Authors:  Cyrille Dreyfus; Nick S Laursen; Ted Kwaks; David Zuijdgeest; Reza Khayat; Damian C Ekiert; Jeong Hyun Lee; Zoltan Metlagel; Miriam V Bujny; Mandy Jongeneelen; Remko van der Vlugt; Mohammed Lamrani; Hans J W M Korse; Eric Geelen; Özcan Sahin; Martijn Sieuwerts; Just P J Brakenhoff; Ronald Vogels; Olive T W Li; Leo L M Poon; Malik Peiris; Wouter Koudstaal; Andrew B Ward; Ian A Wilson; Jaap Goudsmit; Robert H E Friesen
Journal:  Science       Date:  2012-08-09       Impact factor: 47.728

3.  An Efficient Method to Generate Monoclonal Antibodies from Human B Cells.

Authors:  Jenna J Guthmiller; Haley L Dugan; Karlynn E Neu; Linda Yu-Ling Lan; Patrick C Wilson
Journal:  Methods Mol Biol       Date:  2019

4.  The annual production cycle for influenza vaccine.

Authors:  Catherine Gerdil
Journal:  Vaccine       Date:  2003-05-01       Impact factor: 3.641

5.  Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.

Authors:  Wenqian He; Caitlin E Mullarkey; J Andrew Duty; Thomas M Moran; Peter Palese; Matthew S Miller
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

6.  Persistent Antibody Clonotypes Dominate the Serum Response to Influenza over Multiple Years and Repeated Vaccinations.

Authors:  Jiwon Lee; Philipp Paparoditis; Andrew P Horton; Alexander Frühwirth; Jonathan R McDaniel; Jiwon Jung; Daniel R Boutz; Dania A Hussein; Yuri Tanno; Leontios Pappas; Gregory C Ippolito; Davide Corti; Antonio Lanzavecchia; George Georgiou
Journal:  Cell Host Microbe       Date:  2019-02-19       Impact factor: 21.023

7.  Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.

Authors:  Teddy John Wohlbold; Raffael Nachbagauer; Haoming Xu; Gene S Tan; Ariana Hirsh; Karl A Brokstad; Rebecca J Cox; Peter Palese; Florian Krammer
Journal:  mBio       Date:  2015-03-10       Impact factor: 7.867

8.  Distinct patterns of B-cell activation and priming by natural influenza virus infection versus inactivated influenza vaccination.

Authors:  Xiao-Song He; Tyson H Holmes; Mrinmoy Sanyal; Randy A Albrecht; Adolfo García-Sastre; Cornelia L Dekker; Mark M Davis; Harry B Greenberg
Journal:  J Infect Dis       Date:  2014-10-21       Impact factor: 5.226

9.  How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin.

Authors:  Michael B Doud; Juhye M Lee; Jesse D Bloom
Journal:  Nat Commun       Date:  2018-04-11       Impact factor: 14.919

10.  The influenza virus hemagglutinin head evolves faster than the stalk domain.

Authors:  Ericka Kirkpatrick; Xueting Qiu; Patrick C Wilson; Justin Bahl; Florian Krammer
Journal:  Sci Rep       Date:  2018-07-11       Impact factor: 4.379

View more
  23 in total

1.  Librator: a platform for the optimized analysis, design, and expression of mutable influenza viral antigens.

Authors:  Lei Li; Siriruk Changrob; Yanbin Fu; Olivia Stovicek; Jenna J Guthmiller; Joshua J C McGrath; Haley L Dugan; Christopher T Stamper; Nai-Ying Zheng; Min Huang; Patrick C Wilson
Journal:  Brief Bioinform       Date:  2022-03-10       Impact factor: 13.994

Review 2.  Aging and Options to Halt Declining Immunity to Virus Infections.

Authors:  Miguel Ángel Palacios-Pedrero; Albert D M E Osterhaus; Tanja Becker; Husni Elbahesh; Guus F Rimmelzwaan; Giulietta Saletti
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

3.  Antibodies: what makes us stronger.

Authors:  Natalia T Freund
Journal:  Hum Vaccin Immunother       Date:  2021-05-25       Impact factor: 4.526

Review 4.  Plasma cell survival: The intrinsic drivers, migratory signals, and extrinsic regulators.

Authors:  Doan C Nguyen; Meixue Duan; Mohammad Ali; Ariel Ley; Ignacio Sanz; F Eun-Hyung Lee
Journal:  Immunol Rev       Date:  2021-08-01       Impact factor: 10.983

Review 5.  Protein engineering strategies for rational immunogen design.

Authors:  Timothy M Caradonna; Aaron G Schmidt
Journal:  NPJ Vaccines       Date:  2021-12-17       Impact factor: 7.344

Review 6.  Influenza immune escape under heterogeneous host immune histories.

Authors:  Rachel J Oidtman; Philip Arevalo; Qifang Bi; Lauren McGough; Christopher Joel Russo; Diana Vera Cruz; Marcos Costa Vieira; Katelyn M Gostic
Journal:  Trends Microbiol       Date:  2021-07-01       Impact factor: 17.079

7.  Influenza vaccination in the elderly boosts antibodies against conserved viral proteins and egg-produced glycans.

Authors:  Jiwon Jung; Sophia T Mundle; Irina V Ustyugova; Andrew P Horton; Daniel R Boutz; Svetlana Pougatcheva; Ponraj Prabakaran; Jonathan R McDaniel; Gregory R King; Daechan Park; Maria D Person; Congxi Ye; Bing Tan; Yuri Tanno; Jin Eyun Kim; Nicholas C Curtis; Joshua DiNapoli; Simon Delagrave; Ted M Ross; Gregory C Ippolito; Harry Kleanthous; Jiwon Lee; George Georgiou
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

Review 8.  B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat.

Authors:  Jenna J Guthmiller; Henry A Utset; Patrick C Wilson
Journal:  Viruses       Date:  2021-05-22       Impact factor: 5.048

Review 9.  Antibody Focusing to Conserved Sites of Vulnerability: The Immunological Pathways for 'Universal' Influenza Vaccines.

Authors:  Maya Sangesland; Daniel Lingwood
Journal:  Vaccines (Basel)       Date:  2021-02-05

10.  An Egg-Derived Sulfated N-Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines.

Authors:  Jenna J Guthmiller; Henry A Utset; Carole Henry; Lei Li; Nai-Ying Zheng; Weina Sun; Marcos Costa Vieira; Seth Zost; Min Huang; Scott E Hensley; Sarah Cobey; Peter Palese; Patrick C Wilson
Journal:  mBio       Date:  2021-06-15       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.